A new obesity drug has reportedly delivered significant weight loss in clinical trials, with some results suggesting it may be comparable to surgery-level weight loss. The drug, referred to as a triple agonist, has shown promising results in a pivotal phase 3 obesity trial. The development of this drug may represent a breakthrough in the treatment of obesity, although its relationship to other existing or potential weight loss treatments is still unclear.